Zimmer Biomet Holdings, Inc. Logo

Zimmer Biomet Holdings, Inc.

ZIM.DE

(1.5)
Stock Price

106,55 EUR

6.72% ROA

5.19% ROE

42.35x PER

Market Cap.

0,00 EUR

54.49% DER

0% Yield

7.03% NPM

Zimmer Biomet Holdings, Inc. Stock Analysis

Zimmer Biomet Holdings, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Zimmer Biomet Holdings, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE falls within an average range (1.88%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (3.12%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

3 PBV

The stock's PBV ratio (2.14x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

4 DER

The stock maintains a fair debt to equity ratio (51%), indicating a reasonable balance between the money it owes and the ownership it possesses.

5 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

6 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-2.100) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Zimmer Biomet Holdings, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Zimmer Biomet Holdings, Inc. Technical Stock Analysis
# Analysis Recommendation

Zimmer Biomet Holdings, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Zimmer Biomet Holdings, Inc. Revenue
Year Revenue Growth
2000 1.040.600.000
2001 1.178.600.000 11.71%
2002 1.372.400.000 14.12%
2003 1.901.000.000 27.81%
2004 2.980.900.000 36.23%
2005 3.286.100.000 9.29%
2006 3.495.400.000 5.99%
2007 3.897.500.000 10.32%
2008 4.121.100.000 5.43%
2009 4.095.400.000 -0.63%
2010 4.220.200.000 2.96%
2011 4.451.800.000 5.2%
2012 4.471.700.000 0.45%
2013 4.623.400.000 3.28%
2014 4.673.300.000 1.07%
2015 5.997.800.000 22.08%
2016 7.683.900.000 21.94%
2017 7.824.100.000 1.79%
2018 7.932.900.000 1.37%
2019 7.982.200.000 0.62%
2020 6.127.500.000 -30.27%
2021 6.827.300.000 10.25%
2022 7.127.200.000 4.21%
2022 6.939.900.000 -2.7%
2023 7.478.400.000 7.2%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Zimmer Biomet Holdings, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 52.000.000
2001 71.600.000 27.37%
2002 80.700.000 11.28%
2003 105.800.000 23.72%
2004 166.700.000 36.53%
2005 175.500.000 5.01%
2006 188.300.000 6.8%
2007 209.600.000 10.16%
2008 194.000.000 -8.04%
2009 205.400.000 5.55%
2010 220.000.000 6.64%
2011 238.600.000 7.8%
2012 225.600.000 -5.76%
2013 205.000.000 -10.05%
2014 192.800.000 -6.33%
2015 268.800.000 28.27%
2016 365.600.000 26.48%
2017 369.900.000 1.16%
2018 391.700.000 5.57%
2019 519.400.000 24.59%
2020 355.800.000 -45.98%
2021 452.100.000 21.3%
2022 397.600.000 -13.71%
2022 409.000.000 2.79%
2023 472.400.000 13.42%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Zimmer Biomet Holdings, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 429.700.000
2001 532.800.000 19.35%
2002 546.000.000 2.42%
2003 737.500.000 25.97%
2004 1.190.000.000 38.03%
2005 1.259.600.000 5.53%
2006 1.355.700.000 7.09%
2007 1.489.700.000 9%
2008 1.771.300.000 15.9%
2009 1.732.100.000 -2.26%
2010 1.832.400.000 5.47%
2011 1.991.900.000 8.01%
2012 1.912.300.000 -4.16%
2013 1.966.900.000 2.78%
2014 2.050.000.000 4.05%
2015 2.660.500.000 22.95%
2016 3.283.400.000 18.97%
2017 3.369.700.000 2.56%
2018 3.379.300.000 0.28%
2019 3.343.800.000 -1.06%
2020 3.177.800.000 -5.22%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Zimmer Biomet Holdings, Inc. EBITDA
Year EBITDA Growth
2000 291.100.000
2001 264.300.000 -10.14%
2002 414.200.000 36.19%
2003 596.400.000 30.55%
2004 912.700.000 34.66%
2005 1.225.500.000 25.52%
2006 1.365.900.000 10.28%
2007 1.361.100.000 -0.35%
2008 1.396.000.000 2.5%
2009 1.335.600.000 -4.52%
2010 1.200.400.000 -11.26%
2011 1.394.900.000 13.94%
2012 1.428.200.000 2.33%
2013 1.411.500.000 -1.18%
2014 1.383.900.000 -1.99%
2015 1.153.000.000 -20.03%
2016 1.798.100.000 35.88%
2017 1.855.200.000 3.08%
2018 1.058.800.000 -75.22%
2019 2.477.400.000 57.26%
2020 1.841.300.000 -34.55%
2021 2.212.900.000 16.79%
2022 1.882.800.000 -17.53%
2022 2.246.400.000 16.19%
2023 2.394.400.000 6.18%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Zimmer Biomet Holdings, Inc. Gross Profit
Year Gross Profit Growth
2000 749.700.000
2001 852.700.000 12.08%
2002 1.027.600.000 17.02%
2003 1.384.800.000 25.79%
2004 2.201.000.000 37.08%
2005 2.546.700.000 13.57%
2006 2.715.300.000 6.21%
2007 3.021.600.000 10.14%
2008 3.123.800.000 3.27%
2009 3.104.600.000 -0.62%
2010 3.207.800.000 3.22%
2011 3.329.800.000 3.66%
2012 3.346.500.000 0.5%
2013 3.337.300.000 -0.28%
2014 3.423.500.000 2.52%
2015 4.197.200.000 18.43%
2016 5.302.100.000 20.84%
2017 5.691.200.000 6.84%
2018 5.661.000.000 -0.53%
2019 5.783.500.000 2.12%
2020 4.303.200.000 -34.4%
2021 4.866.900.000 11.58%
2022 5.083.200.000 4.26%
2022 4.920.400.000 -3.31%
2023 5.376.400.000 8.48%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Zimmer Biomet Holdings, Inc. Net Profit
Year Net Profit Growth
2000 176.000.000
2001 149.800.000 -17.49%
2002 257.800.000 41.89%
2003 346.300.000 25.56%
2004 541.800.000 36.08%
2005 732.500.000 26.03%
2006 834.500.000 12.22%
2007 773.200.000 -7.93%
2008 848.600.000 8.89%
2009 717.400.000 -18.29%
2010 596.900.000 -20.19%
2011 760.800.000 21.54%
2012 755.000.000 -0.77%
2013 761.000.000 0.79%
2014 720.100.000 -5.68%
2015 147.000.000 -389.86%
2016 305.900.000 51.95%
2017 1.813.800.000 83.13%
2018 -379.200.000 578.32%
2019 1.131.600.000 133.51%
2020 -10.700.000 10675.7%
2021 445.000.000 102.4%
2022 616.000.000 27.76%
2022 290.200.000 -112.27%
2023 838.400.000 65.39%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Zimmer Biomet Holdings, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 1
2001 1 0%
2002 1 100%
2003 2 0%
2004 2 50%
2005 3 0%
2006 3 33.33%
2007 3 0%
2008 4 0%
2009 3 0%
2010 3 -50%
2011 4 50%
2012 4 0%
2013 4 0%
2014 4 0%
2015 1 0%
2016 2 100%
2017 9 87.5%
2018 -2 900%
2019 5 120%
2020 0 0%
2021 2 100%
2022 3 0%
2022 1 -100%
2023 4 75%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Zimmer Biomet Holdings, Inc. Free Cashflow
Year Free Cashflow Growth
2000 203.400.000
2001 117.100.000 -73.7%
2002 186.500.000 37.21%
2003 336.300.000 44.54%
2004 761.400.000 55.83%
2005 772.900.000 1.49%
2006 772.400.000 -0.06%
2007 753.200.000 -2.55%
2008 440.800.000 -70.87%
2009 852.900.000 48.32%
2010 913.300.000 6.61%
2011 888.800.000 -2.76%
2012 1.036.300.000 14.23%
2013 863.100.000 -20.07%
2014 907.900.000 4.93%
2015 649.000.000 -39.89%
2016 1.447.500.000 55.16%
2017 1.426.300.000 -1.49%
2018 1.584.700.000 10%
2019 1.062.800.000 -49.11%
2020 833.600.000 -27.5%
2021 1.082.000.000 22.96%
2022 838.500.000 -29.04%
2022 311.600.000 -169.09%
2023 165.100.000 -88.73%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Zimmer Biomet Holdings, Inc. Operating Cashflow
Year Operating Cashflow Growth
2000 232.400.000
2001 171.800.000 -35.27%
2002 220.200.000 21.98%
2003 494.800.000 55.5%
2004 862.200.000 42.61%
2005 878.200.000 1.82%
2006 1.040.700.000 15.61%
2007 1.084.400.000 4.03%
2008 1.038.100.000 -4.46%
2009 1.117.500.000 7.11%
2010 1.193.500.000 6.37%
2011 1.176.900.000 -1.41%
2012 1.151.900.000 -2.17%
2013 963.100.000 -19.6%
2014 1.052.800.000 8.52%
2015 816.700.000 -28.91%
2016 1.632.200.000 49.96%
2017 1.582.300.000 -3.15%
2018 1.747.400.000 9.45%
2019 1.585.800.000 -10.19%
2020 1.204.500.000 -31.66%
2021 1.499.200.000 19.66%
2022 1.284.700.000 -16.7%
2022 352.500.000 -264.45%
2023 347.900.000 -1.32%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Zimmer Biomet Holdings, Inc. Capital Expenditure
Year Capital Expenditure Growth
2000 29.000.000
2001 54.700.000 46.98%
2002 33.700.000 -62.31%
2003 158.500.000 78.74%
2004 100.800.000 -57.24%
2005 105.300.000 4.27%
2006 268.300.000 60.75%
2007 331.200.000 18.99%
2008 597.300.000 44.55%
2009 264.600.000 -125.74%
2010 280.200.000 5.57%
2011 288.100.000 2.74%
2012 115.600.000 -149.22%
2013 100.000.000 -15.6%
2014 144.900.000 30.99%
2015 167.700.000 13.6%
2016 184.700.000 9.2%
2017 156.000.000 -18.4%
2018 162.700.000 4.12%
2019 523.000.000 68.89%
2020 370.900.000 -41.01%
2021 417.200.000 11.1%
2022 446.200.000 6.5%
2022 40.900.000 -990.95%
2023 182.800.000 77.63%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Zimmer Biomet Holdings, Inc. Equity
Year Equity Growth
2000 261.000.000
2001 78.700.000 -231.64%
2002 366.300.000 78.51%
2003 3.143.300.000 88.35%
2004 3.942.500.000 20.27%
2005 4.682.800.000 15.81%
2006 4.920.500.000 4.83%
2007 5.449.600.000 9.71%
2008 5.650.300.000 3.55%
2009 5.638.700.000 -0.21%
2010 5.771.300.000 2.3%
2011 5.507.200.000 -4.8%
2012 5.860.900.000 6.03%
2013 6.297.300.000 6.93%
2014 6.520.800.000 3.43%
2015 9.887.900.000 34.05%
2016 9.668.900.000 -2.26%
2017 11.735.800.000 17.61%
2018 11.271.300.000 -4.12%
2019 10.430.400.000 -8.06%
2020 10.090.000.000 -3.37%
2021 10.295.300.000 1.99%
2022 9.562.400.000 -7.66%
2022 12.118.400.000 21.09%
2023 9.905.500.000 -22.34%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Zimmer Biomet Holdings, Inc. Assets
Year Assets Growth
2000 597.400.000
2001 745.000.000 19.81%
2002 858.900.000 13.26%
2003 5.156.000.000 83.34%
2004 5.695.500.000 9.47%
2005 5.721.900.000 0.46%
2006 5.974.400.000 4.23%
2007 6.633.700.000 9.94%
2008 7.239.000.000 8.36%
2009 7.785.500.000 7.02%
2010 7.999.900.000 2.68%
2011 8.515.300.000 6.05%
2012 9.012.400.000 5.52%
2013 9.580.600.000 5.93%
2014 9.634.700.000 0.56%
2015 27.219.500.000 64.6%
2016 26.684.400.000 -2.01%
2017 25.964.500.000 -2.77%
2018 24.126.800.000 -7.62%
2019 24.638.700.000 2.08%
2020 24.417.700.000 -0.91%
2021 23.456.400.000 -4.1%
2022 21.066.000.000 -11.35%
2022 21.452.700.000 1.8%
2023 21.294.300.000 -0.74%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Zimmer Biomet Holdings, Inc. Liabilities
Year Liabilities Growth
2000 336.400.000
2001 666.300.000 49.51%
2002 492.600.000 -35.26%
2003 2.005.700.000 75.44%
2004 1.745.900.000 -14.88%
2005 1.036.800.000 -68.39%
2006 1.051.200.000 1.37%
2007 1.181.300.000 11.01%
2008 1.585.100.000 25.47%
2009 2.146.800.000 26.16%
2010 2.228.600.000 3.67%
2011 3.000.500.000 25.73%
2012 3.146.100.000 4.63%
2013 3.280.500.000 4.1%
2014 3.112.100.000 -5.41%
2015 17.330.100.000 82.04%
2016 17.014.500.000 -1.85%
2017 14.229.000.000 -19.58%
2018 12.850.700.000 -10.73%
2019 12.245.900.000 -4.94%
2020 12.218.300.000 -0.23%
2021 10.790.000.000 -13.24%
2022 9.039.000.000 -19.37%
2022 9.328.100.000 3.1%
2023 8.915.700.000 -4.63%

Zimmer Biomet Holdings, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
34.28
Net Income per Share
2.41
Price to Earning Ratio
42.35x
Price To Sales Ratio
0x
POCF Ratio
15.85
PFCF Ratio
0
Price to Book Ratio
2.16
EV to Sales
-0.04
EV Over EBITDA
-0.13
EV to Operating CashFlow
-0.24
EV to FreeCashFlow
-0.4
Earnings Yield
0.02
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
-0,32 Bil.
Graham Number
50.57
Graham NetNet
-35.53

Income Statement Metrics

Net Income per Share
2.41
Income Quality
2.67
ROE
0.05
Return On Assets
0.02
Return On Capital Employed
0.08
Net Income per EBT
0.76
EBT Per Ebit
0.45
Ebit per Revenue
0.2
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.72
Operating Profit Margin
0.2
Pretax Profit Margin
0.09
Net Profit Margin
0.07

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.4
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
6.43
Free CashFlow per Share
3.76
Capex to Operating CashFlow
-0.42
Capex to Revenue
-0.08
Capex to Depreciation
-0.6
Return on Invested Capital
0.07
Return on Tangible Assets
0.07
Days Sales Outstanding
0
Days Payables Outstanding
63.61
Days of Inventory on Hand
408.23
Receivables Turnover
0
Payables Turnover
5.74
Inventory Turnover
0.89
Capex per Share
-2.67

Balance Sheet

Cash per Share
1,52
Book Value per Share
47,19
Tangible Book Value per Share
-6.64
Shareholders Equity per Share
47.19
Interest Debt per Share
26.59
Debt to Equity
0.54
Debt to Assets
0.25
Net Debt to EBITDA
-0.13
Current Ratio
1.96
Tangible Asset Value
-1,39 Bil.
Net Current Asset Value
-4,53 Bil.
Invested Capital
0.54
Working Capital
2,15 Bil.
Intangibles to Total Assets
0.65
Average Receivables
0,00 Bil.
Average Payables
0,38 Bil.
Average Inventory
2258550000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Zimmer Biomet Holdings, Inc. Dividends
Year Dividends Growth
2012 1
2019 0 0%
2020 1 0%
2021 1 0%
2022 0 0%

Zimmer Biomet Holdings, Inc. Profile

About Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. The company is headquartered in Warsaw Indiana, Indiana and currently employs 19,000 full-time employees. The firm's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The firm manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The firm's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.

CEO
Mr. Bryan Hanson
Employee
19.900
Address
345 E Main St
Warsaw Indiana,

Zimmer Biomet Holdings, Inc. Executives & BODs

Zimmer Biomet Holdings, Inc. Executives & BODs
# Name Age

Zimmer Biomet Holdings, Inc. Competitors